The stock price of Elevance Health Inc (NYSE: ELV) has surged by 1.68 when compared to previous closing price of 413.65, but the company has seen a -1.47% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-23 that Elevance Health, Inc.’s Q1 results showed stable Medicare utilization and reaffirmed guidance, in contrast to sector volatility following UnitedHealth Group’s rough earnings miss. Medicaid pressures remain, but rate negotiations and targeted acquisitions may support margin recovery by 2026. Carelon Services is growing rapidly, offering diversification away from premium-driven revenue.
Is It Worth Investing in Elevance Health Inc (NYSE: ELV) Right Now?
Elevance Health Inc (NYSE: ELV) has a higher price-to-earnings ratio of 16.41x compared to its average ratio. ELV has 36-month beta value of 0.67. Analysts have mixed views on the stock, with 14 analysts rating it as a “buy,” 5 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for ELV is 225.49M, and currently, short sellers hold a 1.36% ratio of that float. The average trading volume of ELV on May 01, 2025 was 1.68M shares.
ELV’s Market Performance
The stock of Elevance Health Inc (ELV) has seen a -1.47% decrease in the past week, with a -3.31% drop in the past month, and a 5.07% gain in the past quarter. The volatility ratio for the week is 2.82%, and the volatility levels for the past 30 days are at 3.97% for ELV. The simple moving average for the last 20 days is -1.77% for ELV stock, with a simple moving average of -5.77% for the last 200 days.
Analysts’ Opinion of ELV
Many brokerage firms have already submitted their reports for ELV stocks, with Robert W. Baird repeating the rating for ELV by listing it as a “Neutral.” The predicted price for ELV in the upcoming period, according to Robert W. Baird is $529 based on the research report published on April 15, 2025 of the current year 2025.
Argus, on the other hand, stated in their research note that they expect to see ELV reach a price target of $450. The rating they have provided for ELV stocks is “Buy” according to the report published on March 17th, 2025.
Stephens gave a rating of “Equal-Weight” to ELV, setting the target price at $440 in the report published on January 22nd of the current year.
ELV Trading at 0.38% from the 50-Day Moving Average
After a stumble in the market that brought ELV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.86% of loss for the given period.
Volatility was left at 3.97%, however, over the last 30 days, the volatility rate increased by 2.82%, as shares sank -2.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.96% upper at present.
During the last 5 trading sessions, ELV fell by -1.47%, which changed the moving average for the period of 200-days by -21.47% in comparison to the 20-day moving average, which settled at $428.17. In addition, Elevance Health Inc saw 14.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELV starting from Kaye Mark, who sale 4,588 shares at the price of $424.82 back on Apr 24 ’25. After this action, Kaye Mark now owns 18,977 shares of Elevance Health Inc, valued at $1,949,074 using the latest closing price.
Kaye Mark, the Officer of Elevance Health Inc, proposed sale 4,588 shares at $424.81 during a trade that took place back on Apr 24 ’25, which means that Kaye Mark is holding shares at $1,949,051 based on the most recent closing price.
Stock Fundamentals for ELV
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.63 for the gross margin
The net margin for Elevance Health Inc stands at 0.03. The total capital return value is set at 0.56. Equity return is now at value 14.24, with 5.11 for asset returns.
Based on Elevance Health Inc (ELV), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 2.56. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is 34.29.
Currently, EBITDA for the company is 9.09 billion with net debt to EBITDA at -0.12. When we switch over and look at the enterprise to sales, we see a ratio of 0.49. The receivables turnover for the company is 15.49for trailing twelve months and the total asset turnover is 1.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
To put it simply, Elevance Health Inc (ELV) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
